ZenRx will provide an upfront payment, milestones and royalties.
Zenith Technology Corporation will commit a significant amount of resources to the Oraxol and Oratecan global development programs, providing Kinex and its Asian partner, Hanmi Pharmaceuticals additional clinical programs, supporting global registrations in a non-dilutive fashion.
Kinex Pharmaceuticals licensed the global rights in certain territories outside of Korea, China, India, and Japan, to develop and commercialize the Orascovery program from Hanmi Pharmaceutical Company.
The Orascovery technology has led to the initiation of trials being conducted with both oral formulation of paclitaxel (Oraxol), and oral formulation of Irinotecan (Oratecan).
Kinex Chief Medical Officer Rudolf Kwan said that the Zenith Technology has a reputation as a Clinical Contract Research Organization and its capabilities will be helpful in advancing Kinex global development programs for Oraxol and Oratecan.